RATIONALE: Recent studies suggest that people with asthma of different racial backgrounds may respond differently to various therapies. OBJECTIVES: To use data from well-characterized participants in prior Asthma Clinical Research Network (ACRN) trials to determine whether racial differences affected asthma treatment failures. METHODS: We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10 ACRN trials (1993-2003). Self-declared race was reported in each trial and treatment failure rates were stratified by race. MEASUREMENTS AND MAIN RESULTS: A total of 1,200 unique subjects (whites = 795 [66%]; African Americans = 233 [19%]; others = 172 [14%]; mean age = 32) were included in the analyses. At baseline, African Americans had fewer asthma symptoms (P < 0.001) and less average daily rescue inhaler use (P = 0.007) than whites. There were no differences in baseline FEV(1) (% predicted); asthma quality of life; bronchial hyperreactivity; or exhaled nitric oxide concentrations. A total of 147 treatment failures were observed; a significantly higher proportion of African Americans (19.7%; n = 46) experienced a treatment failure compared with whites (12.7%; n = 101) (odds ratio = 1.7; 95% confidence interval, 1.2-2.5; P = 0.007). When stratified by treatment, African Americans receiving long-acting β-agonists were twice as likely as whites to experience a treatment failure (odds ratio = 2.1; 95% confidence interval, 1.3-3.6; P = 0.004), even when used with other controller therapies. CONCLUSIONS: Despite having fewer asthma symptoms and less rescue β-agonist use, African-Americans with asthma have more treatment failures compared with whites, especially when taking long-acting β-agonists.
RCT Entities:
RATIONALE: Recent studies suggest that people with asthma of different racial backgrounds may respond differently to various therapies. OBJECTIVES: To use data from well-characterized participants in prior Asthma Clinical Research Network (ACRN) trials to determine whether racial differences affected asthma treatment failures. METHODS: We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10 ACRN trials (1993-2003). Self-declared race was reported in each trial and treatment failure rates were stratified by race. MEASUREMENTS AND MAIN RESULTS: A total of 1,200 unique subjects (whites = 795 [66%]; African Americans = 233 [19%]; others = 172 [14%]; mean age = 32) were included in the analyses. At baseline, African Americans had fewer asthma symptoms (P < 0.001) and less average daily rescue inhaler use (P = 0.007) than whites. There were no differences in baseline FEV(1) (% predicted); asthma quality of life; bronchial hyperreactivity; or exhaled nitric oxide concentrations. A total of 147 treatment failures were observed; a significantly higher proportion of African Americans (19.7%; n = 46) experienced a treatment failure compared with whites (12.7%; n = 101) (odds ratio = 1.7; 95% confidence interval, 1.2-2.5; P = 0.007). When stratified by treatment, African Americans receiving long-acting β-agonists were twice as likely as whites to experience a treatment failure (odds ratio = 2.1; 95% confidence interval, 1.3-3.6; P = 0.004), even when used with other controller therapies. CONCLUSIONS: Despite having fewer asthma symptoms and less rescue β-agonist use, African-Americans with asthma have more treatment failures compared with whites, especially when taking long-acting β-agonists.
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: R F Lemanske; C A Sorkness; E A Mauger; S C Lazarus; H A Boushey; J V Fahy; J M Drazen; V M Chinchilli; T Craig; J E Fish; J G Ford; E Israel; M Kraft; R J Martin; S A Nachman; S P Peters; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: G Shapiro; W Lumry; J Wolfe; J Given; M V White; A Woodring; L Baitinger; K House; B Prillaman; T Shah Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: M Kavuru; J Melamed; G Gross; C Laforce; K House; B Prillaman; L Baitinger; A Woodring; T Shah Journal: J Allergy Clin Immunol Date: 2000-06 Impact factor: 10.793
Authors: Elliot Israel; Vernon M Chinchilli; Jean G Ford; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Joanne K Fagan; John V Fahy; James Fish; Monica Kraft; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Stephen B Liggett; Richard J Martin; Nandita Mitra; Stephen P Peters; Eric Silverman; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; Scott T Weiss; Jeffrey M Drazen Journal: Lancet Date: 2004 Oct 23-29 Impact factor: 79.321
Authors: Richard J Martin; Stanley J Szefler; Vernon M Chinchilli; Monica Kraft; Myrna Dolovich; Homer A Boushey; Reuben M Cherniack; Timothy J Craig; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliott Israel; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Stephen P Peters; Christine A Sorkness Journal: Am J Respir Crit Care Med Date: 2002-05-15 Impact factor: 21.405
Authors: C P van Schayck; I D Bijl-Hofland; S G M Cloosterman; H T M Folgering; F J J van der Elshout; C Van Weel Journal: Eur Respir J Date: 2002-02 Impact factor: 16.671
Authors: Michael E Wechsler; Stanley J Szefler; Victor E Ortega; Jacqueline A Pongracic; Vernon Chinchilli; John J Lima; Jerry A Krishnan; Susan J Kunselman; David Mauger; Eugene R Bleecker; Leonard B Bacharier; Avraham Beigelman; Mindy Benson; Kathryn V Blake; Michael D Cabana; Juan-Carlos Cardet; Mario Castro; James F Chmiel; Ronina Covar; Loren Denlinger; Emily DiMango; Anne M Fitzpatrick; Deborah Gentile; Nicole Grossman; Fernando Holguin; Daniel J Jackson; Harsha Kumar; Monica Kraft; Craig F LaForce; Jason Lang; Stephen C Lazarus; Robert F Lemanske; Dayna Long; Njira Lugogo; Fernando Martinez; Deborah A Meyers; Wendy C Moore; James Moy; Edward Naureckas; J Tod Olin; Stephen P Peters; Wanda Phipatanakul; Loretta Que; Hengameh Raissy; Rachel G Robison; Kristie Ross; William Sheehan; Lewis J Smith; Julian Solway; Christine A Sorkness; Lisa Sullivan-Vedder; Sally Wenzel; Steven White; Elliot Israel Journal: N Engl J Med Date: 2019-09-26 Impact factor: 91.245
Authors: Ryan M Dunn; Erik Lehman; Vernon M Chinchilli; Richard J Martin; Homer A Boushey; Elliot Israel; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira L Lugogo; Stephen P Peters; Christine A Sorkness; Stanley Szefler; Michael E Wechsler Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Juan C Celedón; Esteban G Burchard; Dean Schraufnagel; Carlos Castillo-Salgado; Marc Schenker; John Balmes; Enid Neptune; Kristin J Cummings; Fernando Holguin; Kristin A Riekert; Juan P Wisnivesky; Joe G N Garcia; Jesse Roman; Rick Kittles; Victor E Ortega; Susan Redline; Rasika Mathias; Al Thomas; Jonathan Samet; Jean G Ford Journal: Ann Am Thorac Soc Date: 2017-05
Authors: Sharmilee M Nyenhuis; Jerry A Krishnan; Alalia Berry; William J Calhoun; Vernon M Chinchilli; Linda Engle; Nicole Grossman; Fernando Holguin; Elliot Israel; Rick A Kittles; Monica Kraft; Stephen C Lazarus; Erik B Lehman; David T Mauger; James N Moy; Stephen P Peters; Wanda Phipatanakul; Lewis J Smith; Kaharu Sumino; Stanley J Szefler; Michael E Wechsler; Sally Wenzel; Steven R White; Steven J Ackerman Journal: J Allergy Clin Immunol Date: 2017-01-06 Impact factor: 10.793
Authors: Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima Journal: Pulm Pharmacol Ther Date: 2013-02-04 Impact factor: 3.410
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21